SCHEMBL6926570

SCHEMBL6926570

COC(=O)Cc1ccccc1O[C@H]1CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.47
USP30 Q70CQ3 1/20 0.47
GPR119 Q8TDV5 5/20 0.46
PDE4A P27815 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
KDM1A O60341 1/20 0.45
PIK3CD O00329 5/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
KDM4E B2RXH2 1/20 0.44
PKM P14618 1/20 0.44
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
STS P08842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925099 0.94 USP30 (0.48) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL6924027 0.90 L3MBTL1 (0.47) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL6925955 0.89 GPR119 (0.48) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL18295360 0.88 GPR119 (0.50) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL6929074 0.87 GPR119 (0.46) PDE4BUSP30GPR119PRMT5WDR77
SCHEMBL16792796 0.86 USP30 (0.49) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL16814814 0.86 USP30 (0.49) PDE4BUSP30GPR119PDE4APDE4C
SCHEMBL7877839 0.85 HRH1 (0.45) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL534236 0.81 HRH1 (0.46) JAK2JAK1
SCHEMBL6926563 0.81 GPR119 (0.51) PDE4BUSP30GPR119PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515142-B2 Intermediates of aromatic amidine derivatives which have anticoagulation action DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-02-04 US disclosed
US-20020062033-A1 Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-05-23 US disclosed
US-6337405-B1 MULTISTAGE REACTION OF PYRROLE SUBSTITUTED WITH SULFONATE GROUPS AND HYDROXYPHENYLACETIC ACID DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2002-01-08 US disclosed
US-6252088-B1 COUPLING A NITRILE CONTAININ NAPHTHALENE COMPOUND WITH A COMPOUND CONTAINING PROPIONIC ACID GROUP DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-26 US disclosed
EP-0936215-A1 PROCESS FOR PREPARING 2-PHENYL-3-NAPHTHYLPROPIONIC ACID DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020062033-A1 Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives PROC, F12, F2 PDE4B 4737/4885USP30 3729/4885GPR119 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.